{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:38:12Z","timestamp":1789090692722,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873573"],"award-info":[{"award-number":["81873573"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873578"],"award-info":[{"award-number":["81873578"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.clinre.2022.102056","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T11:48:35Z","timestamp":1669290515000},"page":"102056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Inhibition of hepatic NLRP3 inflammasome ameliorates non-alcoholic steatohepatitis\/hepatitis B - induced hepatic injury"],"prefix":"10.1016","volume":"47","author":[{"given":"Feng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2022.102056_bib0001","series-title":"Global hepatitis report","year":"2017"},{"issue":"26","key":"10.1016\/j.clinre.2022.102056_bib0002","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.3748\/wjg.v27.i26.3971","article-title":"Chronic hepatitis B infection with concomitant hepatic steatosis: current evidence and opinion","volume":"27","author":"Shi","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.clinre.2022.102056_bib0003","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2022.102056_bib0004","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.virusres.2015.12.014","article-title":"Recent developments in antivirals against hepatitis B virus","volume":"213","author":"Wang","year":"2016","journal-title":"Virus Res"},{"key":"10.1016\/j.clinre.2022.102056_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.733364","article-title":"Interferon and Hepatitis B: current and future perspectives","volume":"12","author":"Ye","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.clinre.2022.102056_bib0006","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/hep.31150","article-title":"Epidemiological features of NAFLD from 1999 to 2018 in China","volume":"71","author":"Zhou","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.clinre.2022.102056_bib0007","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/ncp.10449","article-title":"Evolution of NAFLD and its management","volume":"35","author":"Mundi","year":"2020","journal-title":"Nutr Clin Pract"},{"issue":"5","key":"10.1016\/j.clinre.2022.102056_bib0008","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","article-title":"Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis","volume":"4","author":"Li","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2022.102056_bib0009","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/liv.14369","article-title":"Chronic hepatitis B and non-alcoholic fatty liver disease: conspirators or competitors?","volume":"40","author":"Zhang","year":"2020","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.clinre.2022.102056_bib0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41422-020-0295-8","article-title":"Toward targeting inflammasomes: insights into their regulation and activation","volume":"30","author":"Christgen","year":"2020","journal-title":"Cell Res"},{"issue":"5","key":"10.1016\/j.clinre.2022.102056_bib0011","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2022.102056_bib0012","article-title":"The NLRP3 inflammasome in non-alcoholic fatty liver disease and steatohepatitis: therapeutic targets and treatment","volume":"13","author":"Yu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinre.2022.102056_bib0013","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6489012","article-title":"Role of NLRP3 inflammasome in the progression of NAFLD to NASH","volume":"2016","author":"Wan","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.clinre.2022.102056_bib0014","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00109-014-1170-1","article-title":"NLRP3 inflammasome activation is required for fibrosis development in NAFLD","volume":"92","author":"Wree","year":"2014","journal-title":"J Mol Med"},{"key":"10.1016\/j.clinre.2022.102056_bib0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.cyto.2018.04.032","article-title":"The role of the NLRP3 inflammasome and the activation of IL-1\u03b2 in the pathogenesis of chronic viral hepatic inflammation","volume":"110","author":"Molyvdas","year":"2018","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.clinre.2022.102056_bib0016","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jhep.2016.12.018","article-title":"HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1\u03b2 production via suppressing the NF-\u03baB pathway and ROS production","volume":"66","author":"Yu","year":"2017","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.clinre.2022.102056_bib0017","doi-asserted-by":"crossref","first-page":"6229","DOI":"10.1002\/jmv.27114","article-title":"The relationship between liver pathological inflammation degree and pyroptosis in chronic hepatitis B patients","volume":"93","author":"Wang","year":"2021","journal-title":"J Med Virol"},{"issue":"3","key":"10.1016\/j.clinre.2022.102056_bib0018","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1124\/pharmrev.120.000171","article-title":"Pharmacological inhibition of the nod-like receptor family pyrin domain containing 3 inflammasome with MCC950","volume":"73","author":"Corcoran","year":"2021","journal-title":"Pharmacol Rev"},{"issue":"12","key":"10.1016\/j.clinre.2022.102056_bib0019","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1111\/j.1440-1746.2012.07268.x","article-title":"Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model","volume":"27","author":"Zhang","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2022.102056_bib0020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.clinre.2022.102056_bib0021","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings","volume":"53","author":"Brunt","year":"2011","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.clinre.2022.102056_bib0022","doi-asserted-by":"crossref","first-page":"E849","DOI":"10.1152\/ajpendo.90996.2008","article-title":"NIH experiment in centralized mouse phenotyping: the Vanderbilt experience and recommendations for evaluating glucose homeostasis in the mouse","volume":"297","author":"McGuinness","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.clinre.2022.102056_bib0023","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.clinre.2022.102056_bib0024","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1053\/j.gastro.2003.11.020","article-title":"Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease","volume":"126","author":"Lonardo","year":"2004","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.clinre.2022.102056_bib0025","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5152\/tjg.2015.150348","article-title":"Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir","volume":"27","author":"Ceylan","year":"2016","journal-title":"Turk J Gastroenterol"},{"issue":"7 Pt 1","key":"10.1016\/j.clinre.2022.102056_bib0026","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1440-1746.2008.05478.x","article-title":"Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors","volume":"23","author":"Peng","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.clinre.2022.102056_bib0027","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.3390\/biomedicines9101491","article-title":"The impact of steatosis on chronic hepatitis C progression and response to antiviral treatments","volume":"9","author":"Siphepho","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.clinre.2022.102056_bib0028","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/liv.13933","article-title":"Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: a population-based cohort study","volume":"39","author":"Zhu","year":"2019","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.clinre.2022.102056_bib0029","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/liv.13271","article-title":"The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response","volume":"37","author":"Charatcharoenwitthaya","year":"2017","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.clinre.2022.102056_bib0030","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","article-title":"Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B","volume":"73","author":"Mak","year":"2020","journal-title":"J Hepatol"},{"issue":"7384","key":"10.1016\/j.clinre.2022.102056_bib0031","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10809","article-title":"Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity","volume":"482","author":"Henao-Mejia","year":"2012","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.clinre.2022.102056_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103008","article-title":"Tumor necrosis factor-alpha induced by hepatitis B virus core mediating the immune response for hepatitis B viral clearance in mice model","volume":"9","author":"Tzeng","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clinre.2022.102056_bib0033","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2147\/DMSO.S206558","article-title":"Novel role of NLRP3-inflammasome in regulation of lipogenesis in fasting-induced hepatic steatosis","volume":"12","author":"Liu","year":"2019","journal-title":"Diabetes Metab Syndr Obes"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740122001899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740122001899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:33:03Z","timestamp":1761895983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740122001899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2210740122001899"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2022.102056","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of hepatic NLRP3 inflammasome ameliorates non-alcoholic steatohepatitis\/hepatitis B - induced hepatic injury","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2022.102056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102056"}}